| Original language | English |
|---|---|
| Pages (from-to) | e636-e640 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 35 |
| Issue number | 10 |
| Early online date | 2021 |
| DOIs |
|
| Publication status | Published - Oct 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of the European Academy of Dermatology and Venereology, Vol. 35, No. 10, 10.2021, p. e636-e640.
Research output: Contribution to journal › Comment/Letter to the editor › Academic
TY - JOUR
T1 - Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study
AU - Mahil, S. K.
AU - Yates, M.
AU - Yiu, Z. Z. N.
AU - Langan, S. M.
AU - Tsakok, T.
AU - Dand, N.
AU - Mason, K. J.
AU - McAteer, H.
AU - Meynell, F.
AU - Coker, B.
AU - Vincent, A.
AU - Urmston, D.
AU - Vesty, A.
AU - Kelly, J.
AU - Lancelot, C.
AU - Moorhead, L.
AU - Bachelez, H.
AU - Capon, F.
AU - Contreras, C. R.
AU - de la Cruz, C.
AU - di Meglio, P.
AU - Gisondi, P.
AU - Jullien, D.
AU - Lambert, J.
AU - Naldi, L.
AU - Norton, S.
AU - Puig, L.
AU - Spuls, P.
AU - Torres, T.
AU - Warren, R. B.
AU - Waweru, H.
AU - the PsoProtect study group
AU - Weinman, J.
AU - Brown, M. A.
AU - Galloway, J. B.
AU - Griffiths, C. M.
AU - Barker, J. N.
AU - Smith, C. H.
N1 - Funding Information: Nothing to disclose: Dr Yates, Dr Dand, Prof. Langan, Dr. Norton, Dr. Tsakok, Dr. Yiu, Dr De La Cruz, Dr. Contreras, Ms. Vesty, Ms. Vincent, Mr. Bola Coker, Ms. Meynell, Dr. Lambert, Prof. Brown, Prof. Naldi. Prof. Barker reports grants and personal fees from Abbvie, grants and personal fees from Novartis, grants and personal fees from Lilly, grants and personal fees from J&J, from null, during the conduct of the study. Prof. Griffiths reports grants and personal fees from AbbVie, grants from Amgen, grants from BMS, grants and personal fees from Janssen, grants from LEO, grants and personal fees from Novartis, grants from Pfizer, grants from Almirall, grants and personal fees from Lilly, grants and personal fees from UCB Pharma, outside the submitted work. Prof. Jullien reports personal fees and non‐financial support from Abbvie, personal fees and non‐financial support from Novartis, personal fees and non‐financial support from Janssen‐Cilag, personal fees and non‐financial support from Lilly, personal fees and non‐financial support from Leo‐Pharma, personal fees and non‐financial support from MEDAC, personal fees and non‐financial support from Celgene, personal fees from Amgen, outside the submitted work. Dr. Capon reports consultancy fees from AnaptysBio, grants from Boheringer‐Ingelheim, outside the submitted work. Prof. Bachelez reports personal fees from Abbvie, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Novartis, personal fees from UCB, personal fees from Almirall, personal fees from Biocad, personal fees from Boehringer‐Ingelheim, personal fees from Kyowa Kirin, personal fees from Pfizer, outside the submitted work. Prof. Gisondi reports personal fees from Abbvie, Amgen, Eli Lilly, Janssen, Novartis, Pierre Fabre, Sandoz, UCB, outside the submitted work. Dr. Galloway reports personal fees from Abbvie, personal fees from Sanofi, personal fees from Novartis, personal fees from Pfizer, grants from Eli Lilly, personal fees from Janssen, personal fees from UCB, outside the submitted work. Prof. Weinmann has presented talks for Abbvie, Abbott, Bayer, Chiesi, Boehringer Ingelheim, Roche and Merck. Dr. Mason reports personal fees from LEO Pharma and Novartis, outside the submitted work. Ms. Moorhead reports personal fees from Abbvie, personal fees from Celgene, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Novartis, personal fees from UCB, outside the submitted work. Dr. Puig reports grants and personal fees from AbbVie, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, personal fees from Fresenius‐Kabi, grants and personal fees from Janssen, grants and personal fees from Lilly, personal fees from Mylan, grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Sandoz, personal fees from Sanofi, personal fees from Samsung‐Bioepis, grants and personal fees from UCB, outside the submitted work. Dr. Mahil reports departmental income from Abbvie, Celgene, Eli Lilly, Janssen‐Cilag, Novartis, Sanofi, UCB, outside the submitted work. Dr. Di Meglio reports grants and personal fees from UCB, personal fees from Novartis, personal fees from Janssen, outside the submitted work. Prof. Warren reports grants and personal fees from Abbvie, grants and personal fees from Celgene, grants and personal fees from Eli Lilly, grants and personal fees from Novartis, personal fees from Sanofi, grants and personal fees from UCB|, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Janssen, grants and personal fees from Leo, grants and personal fees from Pfizer, personal fees from Arena, personal fees from Avillion, personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, outside the submitted work. Prof. Smith reports grants from Abbvie, Sanofi, Novartis, and Pfizer and through consortia with multiple academic partners (psort.org.uk, BIOMAP‐IMI.eu), outside the submitted work. Dr. Torres reports grants and personal fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biogen, Biocad, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung‐Bioepis, Sandoz, during the conduct of the study. Dr. Waweru is on the Board of the International Federation of Psoriasis Associations who have received grants from Abbvie, Almirall, Amgen, Bristol Meyers Squibb, Boehringer Ingelheim, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sun Pharma, Pfizer, and UCB, outside the submitted work. Mr. Urmston reports grants from Almirall, grants from Abbvie, grants from Amgen, grants from Celgene, grants from Dermal Laboratories, grants from Eli Lilly, grants from Janssen, grants from LEO Pharma, grants from T and R Derma, grants from UCB, outside the submitted work. Ms. McAteer reports grants from Abbvie, grants from Almirall, grants from Amgen, grants from Celgene, grants from Dermal Laboratories, grants from Eli Lilly, grants from Janssen, grants from LEO Pharma, grants from UCB, grants from T and R Derma, outside the submitted work. Funding Information: We are grateful to all the patients who have contributed to PsoProtectMe, the professional and patient organisations who supported or promoted PsoProtectMe and for the input of Prof Lars Iversen, Prof Nick Reynolds, Prof Joel Gelfand, Ms Christine Janus and Ms Melissa Sweeney through their vital contributions. We would also like to acknowledge the following individuals for help with translating the PsoProtectMe survey; Dr Haleema Alfailakawi, Dr Wisam Alwan, Dr Rosa Andres Ejarque, Dr Ines Barbosa, Ms Carmen Bugarin Diz, Ms Katarzyna Grys, Dr Mahira Hamdy El Sayed, Mr Tran Hong Truong, Mr Masanori Okuse, Ms Dagmara Samselska, Ms Isabella Tosi, Ms Ya-Hsin Wang, and the Engine Group UK for their generous creative input and website expertise. Funding Information: We acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, the NIHR Manchester Biomedical Research Centre and the Psoriasis Association. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. SKM is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership award (MR/T02383X/1). ND is funded by Health Data Research UK (MR/S003126/1), which is funded by the UK MRC, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; and Wellcome Trust. ZZNY is funded by an NIHR Academic Clinical Lectureship through the University of Manchester. CEMG is an NIHR Emeritus Senior Investigator and is funded in part by the MRC (MR/101 1808/1). CEMG and RBW are in part supported by the NIHR Manchester Biomedical Research Centre. SML is supported by a Wellcome senior research fellowship in clinical science (205039/Z/16/Z); this research was funded in whole or in part by the Wellcome Trust [205039/Z/16/Z]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript (AAM) version arising from this submission. SML is also supported by Health Data Research UK (grant no. LOND1), which is funded by the UK MRC, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/10
Y1 - 2021/10
UR - http://www.scopus.com/inward/record.url?scp=85113788730&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jdv.17450
DO - https://doi.org/10.1111/jdv.17450
M3 - Comment/Letter to the editor
C2 - 34145643
SN - 0926-9959
VL - 35
SP - e636-e640
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 10
ER -